Cardiovascular and renal effects of carperitide and nesiritide in cardiovascular surgery patients: a systematic review and meta-analysis

Critical Care

Makoto Tomita²  Go Haraguchi¹  Toshifumi Kudo¹  Chieko Mitaka³ 

[1] Intensive Care Unit, Tokyo Medical and Dental University Hospital Faculty of Medicine, 1-5-45, Yushima, Bunkyo-ku, Tokyo, 113-8519, Japan;Clinical Research Center, Tokyo Medical and Dental University Hospital Faculty of Medicine, 1-5-45, Yushima, Bunkyo-ku, Tokyo, 113-8519, Japan;Department of Critical Care Medicine, Tokyo Medical and Dental University Graduate School, 1-5-45, Yushima, Bunkyo-ku, Tokyo, 113-8519, Japan

关键词: renal function;    heart failure;    cardiovascular surgery;    B-type (or Brain) natriuretic peptide;    atrial natriuretic peptide;    acute kidney injury;   

Others  :  1093531
DOI  :  10.1186/cc10519

 received in 2011-05-25, accepted in 2011-10-27,  发布年份 2011

【 摘 要 】

Introduction

Acute kidney injury (AKI) following cardiovascular surgery is a common disease process and is associated with both morbidity and mortality. The aim of our study was to evaluate the cardiovascular and renal effects of an atrial natriuretic peptide (ANP, carperitide) and a B-type (or brain) natriuretic peptide (BNP, nesiritide) for preventing and treating AKI in cardiovascular surgery patients.

Methods

Electronic databases, including PubMed, EMBASE and references from identified articles were used for a literature search.

Results

Data on the infusion of ANP or BNP in cardiovascular surgery patients was collected from fifteen randomized controlled trials and combined. The infusion of ANP or BNP increased the urine output and creatinine clearance or glomerular filtration rate, and reduced the use of diuretics and the serum creatinine levels. A meta-analysis showed that ANP infusion significantly decreased peak serum creatinine levels, incidence of arrhythmia and renal replacement therapy. The meta-analysis also showed that ANP or BNP infusion significantly decreased the length of ICU stay and hospital stay compared with controls. However, the combined data were insufficient to determine how ANP or BNP infusion during the perioperative period influences long-term outcome in cardiovascular surgery patients.

Conclusions

The infusion of ANP or BNP may preserve postoperative renal function in cardiovascular surgery patients. A large, multicenter, prospective, randomized controlled trial will have to be performed to assess the therapeutic potential of ANP or BNP in preventing and treating AKI in the cardiovascular surgical setting.

【 授权许可】

   
2011 Mitaka et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

Figure 4.

【 参考文献 】

• [1]Appoo J, Norris C, Merali S, Graham MM, Koshal A, Knudtson ML, Ghali WA: Long-term outcome of isolated coronary artery bypass surgery in patients with severe left ventricular dysfunction. Circulation 2004, 110(Suppl II):13-17.
• [2]Ahmed WA, Tully PJ, Baker RA, Knight JL: Survival after isolated coronary artery bypass grafting in patients with severe left ventricular dysfunction. Ann Thorac Surg 2009, 87:1106-1112.
• [3]Ronco C, Haapio M, House AA, Anavekar N, Bellomo R: Cardiorenal syndrome. J Am Coll Cardiol 2008, 52:1527-1539.
• [4]Loef BG, Epema AH, Navis G, Ebels T, Stegeman CA: Postoperative renal dysfunction and preoperative left vetricular dysfunction predispose patients to increased long-term mortality after coronary bypass graft surgery. Br J Anaesth 2009, 102:749-755.
• [5]Karkouti K, Wijeysundera DN, Yau TM, Callum JL, Cheng DC, Crowther M, Dupuis J-Y, Fremes SE, Kent B, Laflamme C, Lamy A, Legare J-F, Mazer CD, McCluskey SA, Rubens FD, Sawchuk C, Beattie WS: Acute kidney injury after cardiac surgery; focus on modifiable risk factors. Circulation 2009, 119:495-502.
• [6]Thakar CV, Worley S, Arrigain S, Yared J-P, Paganini EP: Influence of renal dysfunction on mortality after cardiac surgery: modifying effect of preoperative renal function. Kidney Int 2005, 67:1112-1119.
• [7]Dasta JF, Kane-Gill SL, Durtschi AJ, Pathak DS, Kellum JA: Costs and outcomes of acute kidney injury (AKI) following cardiac surgery. Nephrol Dial Transplant 2008, 23:1970-1974.
• [8]Levin ER, Gardner DG, Samson WK: Natriuretic peptides. N Engl J Med 1998, 339:321-328.
• [9]Marin-Grez M, Fleming JT, Steinhausen M: Atrial natriuretic peptide causes pre-glomerular vasodilatation and post-glomerular vasoconstriction in rat kidney. Nature 1986, 324:473-476.
• [10]Shaw SG, Weidmann P, Hodler J, Zimmermann A, Patemostro A: Atrial natriuretic peptide protects against acute ischemic renal failure in the rat. J Clin Invest 1987, 80:1232-1237.
• [11]Hirata Y, Habuka K, Narumi Y, Yokoyama K, Makita K, Imai T: Atrial natriuretic peptide infusion improves ischemic renal failure after suprarenal abdominal aortic cross-clamping in dogs. Crit Care Med 2003, 31:2205-2210.
• [12]Rademaker MT, Richards AM: Cardiac natriuretic peptide for cardiac health. Clin Sci 2005, 108:23-36.
• [13]Kuhn M: Cardiac and intestinal natriuretic peptides: insights from genetically modified mice. Peptides 2005, 26:1078-1085.
• [14]Houben AJ, van der Zander K, de Leeuw PW: Vascular and renal actions of brain natriuretic peptide in man: physiology and pharmacology. Fundam Clin Pharmacol 2005, 19:411-419.
• [15]Abassi Z, Karram T, Ellaham S, Winaver J, Hoffman A: Implications of the natriuretic peptide system in the pathogenesis of heart failure: diagnostic and therapeutic importance. Pharmacol Ther 2004, 102:223-241.
• [16]D'Souza SP, Davis M, Baxter GF: Autocrine and paracrine actions of natriuretic peptides in the heart. Pharmacol Ther 2004, 101:113-129.
• [17]Colucci WS, Elkayam U, Horton DP, Abraham WT, Bouge RC, Johnson AD, Wagoner LE, Givertz MM, Liang C-S, Neibaur M, Haught H, LeJemtel TH, for the Nesiritide Study Group: Intravenous nesiritide, a natriuretic peptide, in the treatment of decompensated congestive heart failure. N Engl J Med 2000, 343:246-253.
• [18]Publication Committee for the VMAC Investigators (Vasodilation in the Management of Acute CHF): Intravenous nesiritide vs. nitroglycerin for treatment of decompensated congestive heart failure: a randomized controlled trial. JAMA 2002, 287:1531-1540.
• [19]Mitaka C, Kudo T, Haraguchi G: Effects of atrial natriuretic peptide on renal function in patients undergoing cardiovascular surgery. J Jpn Soc Intensive Care Med 2011, 18:201-206. (in Japanese)
• [20]Moher D, Liberati A, Tetzlaff J, Altman DG, The PRISMA Group: Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PloS Med 2009, 6:e1000097.
• [21]Sezai A, Shiono M, Orime Y, Hata H, Hata M, Negishi N, Sezai Y: Low-dose continuous infusion of human atrial natriuretic peptide during and after cardiac surgery. Ann Thorac Surg 2000, 69:732-738.
• [22]Bergman A, Odar-Cederlόf I, Westman L, Ohqvist G: Effects of human atrial natriuretic peptide in patients after coronary artery bypass surgery. J Cardiothorac Vasc Anesth 1996, 10:490-496.
• [23]Sezai A, Hata M, Wakui S, Niino T, Takayama T, Hirayama A, Saito S, Minami K: Efficacy of continuous low-dose hANP administration in patients undergoing emergent coronary artery bypass grafting for acute coronary syndrome. Circ J 2007, 71:1401-1407.
• [24]Mitaka C, Kudo T, Jibiki M, Sugano N, Inoue Y, Makita K, Imai T: Effects of human natriuretic peptide on renal function in patients undergoing abdominal aortic aneurysm repair. Crit Care Med 2008, 36:745-751.
• [25]Swärd K, Valsson F, Odencrants P, Samuelsson O, Ricksten S-E: Recombinant human atrial natriuretic peptide in ischemic acute renal failure: a randomized placebo-controlled trial. Crit Care Med 2004, 32:1310-1315.
• [26]Sezai A, Hata M, Niino T, Yoshitake I, Unosawa S, Wakui S, Osaka S, Takayama T, Kasamaki Y, Hirayama A, Minami K: Influence of continuous infusion of low-dose human atrial natriuretic peptide on renal function during cardiac surgery. J Am Coll Cardiol 2009, 54:1058-1064.
• [27]Sezai A, Hata M, Niino T, Yoshitake I, Unosawa S, Wakui S, Fujita K, Takayama T, Kasamaki Y, Hirayama A, Minami K: Continuous low-dose infusion of human atrial natriuretic peptide in patients with left ventricular dysfunction undergoing coronary artery bypass grafting. J Am Coll Cardiol 2010, 55:1844-1851.
• [28]Mentzer RM, Oz MC, Sladen RN, Graeve AH, Hebeler RF, Luber JM Jr, Smedira NG, on behalf of the NAPA Investigators: Effects of perioperative nesiritide in patients with left ventricular dysfunction undergoing cardiac surgery. J Am Coll Cardiol 2007, 49:716-726.
• [29]Chen HH, Sundt TM, Cook DJ, Heublein DM, Burnett JC Jr: Low dose nesiritide and the preservation of renal function in patients with renal dysfunction undergoing cardiopulmonary-bypass surgery. A double-blind placebo-controlled pilot study. Circulation 2007, 116(suppl I):134-138.
• [30]Ejaz AA, Martin TD, Johson RJ, Winterstein AG, Klodell CT, Hess PJ Jr, Ali AK, Whidden EM, Staples NL, Alexander JA, House-Fancher MA, Beaver TM: Prophylactic nesiritide does not prevent dialysis or all-cause mortality in patients undergoing high-risk cardiac surgery. J Thorac Cardiovasc Surg 2009, 138:959-964.
• [31]Beaver TM, Winterstein A, Hess PJ Jr, Martin TD, Arnaoutakis GJ, Peng YG, Ejaz AA: Nesiritide following maze and mitral valve surgery. J Card Surg 2008, 23:431-436.
• [32]Hayashi Y, Ohtani M, Hiraishi T, Kobayashi Y, Nakamura T: Synthetic human α-atrial natriuretic peptide infusion in management after open heart operations. ASAIO Journal 2003, 49:320-324.
• [33]Sumi K, Iida H, Yamaguchi S, Fukuoka N, Shimabukuro K, Dohi S: Human atrial natriuretic peptide prevents the increase in pulmonary artery pressure associated with aortic unclamping during abdominal aortic aneurysmectomy. J Cardiothorac Vasc Anesth 2008, 22:204-209.
• [34]Hayashida N, Chihara S, Kashikie H, Tayama E, Yokose S, Akasu K, Aoyagi S: Effects of intraoperative administration of atrial natriuretic peptide. Ann Thorac Surg 2000, 70:1319-1326.
• [35]Izumi K, Eishi K, Yamachika S, Hashizume K, Tada S, Yamane K, Takai H, Tanigawa K, Miura T, Nakaji S: The efficacy of human atrial natriuretic peptide in patients with renal dysfunction undergoing cardiac surgery. Ann Thorac Cardiovasc Surg 2008, 14:294-302.
• [36]Hobson CE, Yavas S, Segal MS, Schold JD, Tribble CG, Layon AJ, Bihorac A: Acute kidney injury is associated with increased long-term mortality after cardiothoracic surgery. Circulation 2009, 119:2444-2453.
• [37]Brown JR, Kramer RS, Coca SG, Parikh CR: Duration of acute kidney injury impacts long-term survival after cardiac surgery. Ann Thorac Surg 2010, 90:1142-1149.
• [38]Abu-Omar Y, Ratnatunga C: Cardiopulmonary bypass and renal injury. Perfusion 2006, 21:209-213.
• [39]Bellomo R, Auriemma S, Fabbri A, D'onofrio A, Katz N, McCullough PA, Ricci Z, Shaw A, Ronco C: The pathophysiology of cardiac surgery-associated acute kidney injury (CSA-AKI). Int J Artif Organs 2008, 31:166-178.
• [40]Chong T, Nguyen L, Owens CD, Conte MS, Belkin M: Suprarenal aortic cross-clamping position: a reappraisal of its effects on outcomes for open abdominal aortic aneurysm repair. J Vasc Surg 2009, 49:873-880.
• [41]Gelman S: The pathophysiology of aortic cross-clamping and unclamping. Anesthesiology 1995, 82:1026-1060.
• [42]Ho KM, Sheridan D: Meta-analysis of frusemide to prevent or treat acute renal failure. BMJ 2006, 333:420.
• [43]Kiberd BA, Larson TS, Robertson CR, Jamison RL: Effect of atrial natriuretic peptide on vasa recta blood flow in the rat. Am J Physiol 1987, 252:F1112-F1117.
• [44]Brochard L, Abroug F, Brenner M, Broccard AF, Danner RL, Ferrer M, Laghi F, Magder S, Papazian L, Pelosi P, Polderman KH, on behalf of the ATS/ERS/ESICM/SCCM/SRLF Ad Hoc Committee on Acute Renal Failure: An official ATS/ERS/ESICM/SCCM/SRLF statement: prevention and management of acute renal failure in the ICU patient. Am J Respir Crit Care Med 2010, 181:1128-1155.
• [45]Nishikimi T, Kuwahara K, Nakao K: Current biochemistry, molecular biology, and clinical relevance of natriuretic peptides. J Cardiol 2011, 57:131-140.
• [46]Nakajima K, Onishi K, Dohi K, Tanabe M, Kurita T, Yamanaka T, Ito M, Isaka N, Nobori T, Nakano T: Effects of human atrial natriuretic peptide on cardiac function and hemodynamics in patients with high plasma BNP levels. Int J Cardiol 2005, 104:332-337.
• [47]Perrone RD, Madias NE, Levey AS: Serum creatinine as an index of renal function: new insight into old concepts. Clin Chem 1992, 38:1933-1953.